An even bigger opportunity for Opko Health next year may be the launch of its wholly owned vitamin D prohormone, Rayaldee. Rayaldee notched an FDA go-ahead for use in chronic kidney disease (CKD) patients this past summer and Frost plans to begin selling it this quarter.